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Abstract
Background: HCV is prevalent throughout the world. It is a major cause of chronic liver disease. There is no
effective vaccine and the most common therapy, based on Peginterferon, has a success rate of ~50%. The
mechanisms underlying viral resistance have not been elucidated but it has been suggested that both host and
virus contribute to therapy outcome. Non-structural 5A (NS5A) protein, a critical virus component, is involved in
cellular and viral processes.
Methods: The present study analyzed structural and functional features of 345 sequences of HCV-NS5A genotypes
1 or 3, using in silico tools.
Results: There was residue type composition and secondary structure differences between the genotypes. In
addition, second structural variance were statistical different for each response group in genotype 3. A motif search
indicated conserved glycosylation, phosphorylation and myristoylation sites that could be important in structural
stabilization and function. Furthermore, a highly conserved integrin ligation site was identified, and could be linked
to nuclear forms of NS5A. ProtFun indicated NS5A to have diverse enzymatic and nonenzymatic activities,
participating in a great range of cell functions, with statistical difference between genotypes.
Conclusion: This study presents new insights into the HCV-NS5A. It is the first study that using bioinformatics
tools, suggests differences between genotypes and response to therapy that can be related to NS5A protein
features. Therefore, it emphasizes the importance of using bioinformatics tools in viral studies. Data acquired herein
will aid in clarifying the structure/function of this protein and in the development of antiviral agents.
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Introduction
Hepatitis C is a major health problem; it is highly preva-
lent worldwide and has a high probability of persistence
[1,2]. Chronic persistence can result in cirrhosis and
hepatocellular carcinoma [3,4]. Hepatitis C virus (HCV)
is member of the Flaviviridae family within the Hepaci-
virus genus, although many of its features are distinct
from other family members including the structural
organization of the protein and the 5’-cap independent
translation [5].
On the basis of viral variability, HCV is classified into
seven genotypes and more than 50 subtypes [6]. In
addition, an infected patient will harbour different but
related viral genomes known as quasispecies. This high
variability can be explained by a combination of three
factors: (1) viral RNA polymerase acts without proof-
reading [7]; (2) HCV has co-evolved with human popu-
lations for millions of years [8]; (3) the viral life cycle is
fast, resulting in the production of approximately 1.3 ×
1012 virions per patient per day [9].
T h eH C VR N Ag e n o m et r a n s l a t e sap o l y p r o t e i nt h a t
is cleaved by viral and host proteases to generate ten
structural and non-structural proteins [10-12]. Among
the non-structural proteins, NS5A is a phosphoprotein
critical for the HCV life cycle. It is composed of
approximately 447 amino acids and may participate in
viral RNA replication, modulation of cell signaling path-
ways, interferon response, pathogenesis and apoptosis
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structure have yet to be elucidated. However, evidence
suggests that it functions through interaction with other
HCV and host cell proteins [13-16].
NS5A is divided into three domains [17,18]. Domain I
contains a membrane binding domain [19,20] and a zinc
finger domain that are essential for HCV replication
[ 1 7 ] .D o m a i nI Ia n dI I Ia r en a turally unstructured, per-
forming function by interacting with several proteins
[15,21].
The importance of NS5A protein in disease caused by
hepatitis C is unquestioned. However, difficulties with
experimental methods used to determine the structures
of highly flexible proteins have resulted in a poor under-
standing of the overall structure and functions of NS5A.
Such difficulties have led to the development of bioin-
formatic tools that are helpful in obtaining reliable data
for these types of proteins. Ab initio tools are also
important for studying proteins with low or no homol-
ogy, and can be used to compare them with experimen-
tally determined structures.
In the present study, complete sequences from HCV
NS5A genotypes 1 and 3 were analyzed. These
sequences were obtained from Brazilian patients who
showed different responses toP e g i n t e r f e r o n( P e g I F N )
therapy. Using these sequences, the aims were to ana-
lyze structural and functional features. The knowledge
obtained should aid in the design of new drugs and vac-
cines, and in developing other resources to improve
HCV therapy.
Results
Amino acid composition and secondary structure of NS5A
Therapy response did not differ according to the amino
acids composition or the secondary structure type com-
position. However, considering the genotypes, the aver-
age percentages of alanine, glutamic acid, glutamine and
tyrosine present in the NS5A protein were different
between the genotypes 1a, 1b and 3. The average percen-
tages of cysteine, valine and threonine differed between
genotype 1 and 3. All sequences obtained from genotype
1b presented with 2% tyrosine (data not shown). Second-
ary structure analysis demonstrated that distribution of
each secondary structure type followed a normal distri-
bution. Statistical analysis (t-test) suggests that the three
secondary arrangements are high significant factors (p-
value < .001) to differ the genotypes. Composition of
helix, sheet or coil in percentage did not result in signifi-
cant difference when we compared these three arrange-
ments the therapy outcome responses (Figure 1A-C). In
contrast, when we compared the variation of these com-
positions among the response groups, there is a great
(and statistical) difference, especially in genotype 3. Test
for equal variances (Bartlett’s test and Levene’st e s t )
resulted in different variation behaviour comparing the
three outcome responses sequences in genotype 3 (Figure
2A-C). The same test applied for analysis intra-response
group indicates that even when sequences are from dif-
ferent patients, if they are from the same therapy out-
come group, they are not significantly different (p > .05)
(Table 1).
Transmembrane regions and pattern/motif search
MEMSAT3 analysis demonstrated that all NS5A and
reference sequences contained a possible transmem-
brane region between residues 32 and 51, and Prosite
recognized seven functional patterns in each NS5A
sequence. No relationship was observed between therapy
response or genotype and pattern number or motif loca-
tion. Table 2 presents a summary of each conserved pat-
tern/motif encountered in the NS5A analysis. Between
two and seven N-glycosylation sites were present within
the same sequence. In two positions (69 and 268), this
pattern was conserved in 90% of sequences; this motif
was absent at these positions in 4% of cases. cAMP- and
cGMP-dependent protein kinase phosphorylation sites
were identified; 90% of sequences had a minimum of
one such motif at position 357, but 4% of sequences
from one patient lacked this motif. Protein kinase C
(PKC) phosphorylation sites were present in all
sequences at positions 71 and 238. The number of these
sites in the same sequence ranged from five to eight.
Casein kinase II phosphorylation sites were recognized
in non-conserved positions, being present between 4
and 8 times in the same sequence. Tyrosine kinase
phosphorylation sites were identified in a conserved
position (residue 122 or 123). N-myristoylation sites
were present in various numbers and several positions,
with NS5A sequences possessing between four and eight
of these motifs in the same sequence. A cell attachment
sequence (RGD sequence) was present in all sequences,
conserved in number and position; NS5A sequences
possessed this motif at position 48. Figure 3 summarizes
the results of the MEMSAT3 and Prosite analyses in the
reference sequence AF009606.
Prediction of functional features
ProtFun analysis results are detailed in Table 3. It indi-
cated that the complete NS5A has properties similar to
proteins which play role in regulatory functions, replica-
tion and transcription, central intermediary metabolism
or purines/pyrimidines. All sequences were classified as
an enzyme of unknown class, with the transcription reg-
ulation as the gene ontology category. Calculated chi-
square test showed significant difference (p <0 . 0 5 )
between therapy outcome groups and between geno-
types related to functional category predicted, with sta-
tistical power level varying from 0.617 to 1.
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Page 2 of 10The results from NS5A domain I suggested that this
region is related to the functional category of energy
metabolism, with enzymatic activity from unknown
class. For domain I, prediction of gene ontology category
varied among transcription regulation, growth factor,
immune response, transcription and none of these cate-
gories. To calculate the chi-square, categories below 5
sequences were excluded. Significant difference was
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Figure 1 Statistical analysis in second Structure composition (%) distribution of the NS5A sequences. Plot: Difference in helix (A), sheet
(B) and coil (C) percentage in the NS5A protein between genotype 1 and 3/therapy outcome. X-axis describes the percentage of each second
structure type in total protein; y-axis means density (number of sequences with correspond percentage/total number of sequences) ETR-End of
therapy responder, NR-nonresponder, R-responder.
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Page 3 of 10observed between genotypes but not between therapy
response groups, with statistical power of 0.999.
Prediction for domain II sequences varied in func-
tional category, enzymatic function and gene ontology
category. Resulted functional category includes energy
metabolism and translation, with statistical difference
between therapy outcome groups (except between non-
responders–NR and end of therapy responders- ETR
groups) and genotype. Enzymatic function prediction
and gene ontology (GO) category prediction had signifi-
cant difference between genotypes, with statistical power
of 0.801 and 1, respectively.
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Figure 2 Statistical analysis in second structure composition (%) variance of the NS5A genotype 3 sequences. Plot: Statistical results for
helix (A), sheet (B) and coil (C) variance in genotype 3. Square in the left shows the calculated values for each test. Note the variance different
distribution in each response group. StDev-standard deviation.
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Page 4 of 10For domain III analysis, all the sequences were pre-
dicted to be similar to proteins related to transport and
binding, with nonenzyme function. The gene ontology
category varied among growth factor, immune response,
stress response, hormone, voltage-gated ion channel and
unknown. These differences were significant different
between end of therapy responders (ETR) sequences
and the other two outcome groups (non-responders–
NR, responders–R) and between genotypes. Statistical
power values were 0.6 and 1, respectively.
Discussion
Infection with genotype 1 results in lower therapy suc-
cess rates than other genotypes [22]. No previous study
was found connecting NS5A amino acids composition
or secondary structure type (Figure 1, 2 and Table 1) to
this difference in response rate. The present study sug-
gests that these two characteristics present genotypic
differences. These differences could affect NS5A func-
tions, by modifying its interactions with other viral and
host proteins, or its stability. Consequently, these differ-
ences could affect viral resistance, replication and other
properties linked to NS5A that differ among genotypes.
Indeed, some observations of the viral genotype speci-
fic features are reported between genotype 1 and 2.
Viral dynamics was the first property detected, in a
study that collected viral load data in patients receiving
IFN therapy. Viral kinetics was greatly different. In gen-
otype 1 infected patients, IFN effectiveness, free virion
clearance rate and cell death rate were lower than geno-
type 2 HCV hosts. In contrast, percentage of individuals
that reached an undetectable level during 14 days of
therapy was higher in genotype 2 infected individuals
[23]. Our group also found in vivo indication of diver-
gences in NS5A quasispecies composition and muta-
tional profiles between genotypes 1 and 3 in baseline
specimens [24,25]. Using the sequences derived from
these studies, we showed that there is indication of
structural and functional differences between NS5A-1a/
b and NS5A-3 (Table 3). In addition, at least for geno-
type 3, there were differences in variance of structure
between the different responses groups (Figure 2). This
divergence is not observed when we compare the
sequences extracted from patients with the same therapy
response. Possibly resulting from the structural differ-
ences, the functional prediction profile was also different
between genotypes.
In vivo and derived in silico results point to a relation-
ship between NS5A and genotypic IFN response rate.
However, in vitro researches results are still controversial.
In 2008, it was reported that cells infected by 2a-NS5A-
containing replicons presented lower degree of IFN antag-
onism than the counterpart containing 1b-NS5A. The
same study also found suggestions that the V3 domain
and the C-terminal region of the NS5A are related to IFN
differential reaction [26]. Other study in 2010 did not
reached similar conclusions. In this case, cells expressing
1b and 2a NS5A protein presented analogous capability of
IFN responses inhibition and IL-8 expression induction.
The author suggests that other viral factors and/or host
factors may be involved in the genotypic difference of
HCV [27]. Posterior, it was also described that HCV with
recombinant NS5A from different genotypes presents dif-
ferent sensibility to NS5A inhibitors, but not for IFN [28].
These hypothesis does support our group results, since it
seems that NS5A has still numerous unknown direct and
indirect interactions with host and viral proteins, conse-
quence from the high structural flexibility observed in
domains II and III of the protein [15,21].
Table 1 Statistical results (t-test) for comparison between
genotype 1 and 3 secondary structure composition
Genotype No. of sequences (n) Mean StDev SE Mean p-value
a-helix
1 109 18.06 0.52 0.05 0.00
3 143 17.51 0.41 0.03
b-sheet
1 109 19.58 0.27 0.03 0.00
3 143 18.61 0.33 0.03
Coil
1 109 62.35 0.52 0.05 0.00
3 143 63.88 0.38 0.03
StDev: Standard Deviation, SE: Standard Error
Table 2 Conservation of patterns/motifs predicted on NS5A, described in percentage of sequences
Motif/pattern name Presence Conserved Positions No. of sites in same sequence
N-glycosylation 95,65% 69, 268 (90%) Two up to six
cAMP/cGMP-dependent phosphorylation 95,65% 357 (90, 14%) One up to two
PKC phosphorylation 100% 71, 238 (98, 84%) Five up to eight
CKII phosphorylation 100% - Four up to eight
Tyrosine kinase phosphorylation 99,99% 122 or 123(99, 99%) Four up to eight
N-myristoylation 100% - Four up to eight
Cell attachment sequence 100% 48 (100%) 1
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Page 5 of 10High structural flexibility is the key of the multifunc-
tionality in promiscuous proteins [29]. The NS5A pro-
tein, as other promiscuous proteins, presents an
intrinsic disorder. Recent studies showed that the
domain III can be unfold or partially fold in helix [21],
another feature of promiscuous proteins, which can pre-
sent different conformations depending on the interac-
tions made [29]. Our secondary structure prediction
shows a high percentage of coils in NS5A, which results
in the high structural flexibility of the NS5A. In addition
with ProtFun predictions, we observed that NS5A may
have genotypic differences in performed functions, vary-
ing also between the domains, with a great statistical
difference (p < .001) and power (> .95) (Table 3).
Despite of the essential functions for HCV infection,
NS5A from different genotypes may have different
Table 3 Statistical results for comparison between therapy outcome and genotype in ProtFun analysis
Region Feature Comparison Chi-square p-value Stat power
NS5A Functional category Outcome 18.832 0.004 0.711
R and NR 10.697 0.013 0.617
R and ETR 15.279 0.002 0.627
NR and ETR 5.103 0.164 0.676
Genotype 218.730 0.000 1
Domain I GO* Outcome 1.370 0.504 0.694
Genotype 51.316 0.000 0.999
Domain II Functional category Outcome 27.769 0.000 0.861
R and NR 15.903 0.000 0.881
R and ETR 16.776 0.000 0.581
NR and ETR 0.241 0.623 0.663
Genotype 21.755 0.000 0.780
Non/enzyme Genotype 22.711 0.000 0.801
GO Outcome 1.792 0.408 0.665
Genotype 116.636 0.000 1
Domain III GO* Outcome 24.680 0.000 0.572
R and NR 5.488 0.064 0.587
R and ETR 11.307 0.010 0.616
ETR and NR 12.374 0.006 0.609
Genotype 54.217 0.000 0.998
*values < 05 were excluded for the statistical calculation
Figure 3 Results of MEMSAT3 and Prosite. Summary for NS5A reference AF009606. TM: transmembrane region, CRS: cytoplasmic retention
site, PKR-bd: PKR binding site, NLS: nuclear localization site, V3: variable region 3. Lines-purple: n-glycosylation sites, blue: phosphorylation sites,
green: n-myristoylation sites, orange: RGD site.
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Page 6 of 10secondary functions. These functions may lead directly
or indirectly to the different SVR rate in genotypes.
Also, it would explain why NS5A from different geno-
types have different behaviour when the mutational and
quasispecies profile are analysed [24,25].
Prosite analysis demonstrated the presence of several
potential co-and post-translational modification sites
that are well conserved in the sequence, including N-
glycosylation sites (Figure 3 and Table 2). Carbohydrate
binding can confer a different function on a protein. For
example, it can lead to the addition of epitopes that
facilitate the recognition of other proteins [30,31]. There
are no studies that describe glycosylation of NS5A, but
in some viruses, glycosylated proteins can be essential
for viral assembly [32]. Helenius (1994) demonstrated
that glycosylation promoted an increase in solubility,
and possibly in interactions with chaperones on the
endoplasmatic reticulum, thereby affecting folding and
stabilization of the protein. Proteins without this modifi-
cation could assemble in a non-reversable form or exit
the endoplasmatic reticulum [33]. N- and O-linked gly-
cosylation are also described in non-reticulum compart-
ments, such as nucleus and cytosol [34]. Since this
discover, several cytosolic proteins involved in the pro-
cess of adding carbohydrate to proteins were character-
ized [35,36]. Proteins which undergo these unusual
glycosylation processes are linked with several functions,
including nuclear membrane structure and transcription
factors [37].
Following this hypothesis, NS5A glycosylation may be
essential for maintaining its functional structure, as
these modifications sequence appear to be conserved. In
addition, this modification may play an important role
in nuclear localization of NS5A mutants.
Potential phosphorylation sites were identified in
NS5A. This modification has been experimentally
described and is important for interaction with core
proteins and for viral assembly [38]. Phosphorylation is
a reversible modification process, and may be key to the
multifunctionality of NS5A. Several proteins were identi-
fied as playing a role in NS5A phosphorylation including
AKT, p70s6K, MEK, MKK1, CKI, CKIIe and Syk [39-41]
but we found no study has described phosphorylation by
PKC or cAMP-/cGMP-dependent protein kinase. These
proteins are still candidates for this process, as details
concerning NS5A phosphorylation have yet to be fully
elucidated.
Possible myristoylation sites with qualitative conserva-
tion were recognized in NS5A. Covalent myristate bind-
ing is not reversible and alters the protein’s
hydrophobicity. In viral proteins such as Arenavirus and
Arterivirus, this modification is related to functions such
as protein cell localization and protein-protein interac-
tions [42,43]. There are no studies describing
myristoylation in the NS5A protein. However, we sug-
gest that this process is important in structural/func-
tional stabilization of NS5A. If experimental data
demonstrated that these modifications are present in
NS5A, these sites could be possible targets for new anti-
viral agents.
Interestingly, a cell attachment site (RGD) was present
in all sequences between residues 48 and 52. This region
is inside the trasmembrane region predicted by MEM-
SAT3. RGD is a sequence for interaction with integrins,
proteins located on the cell surface that act on cell-cell
and cell-extracellular matrix interactions [44]. Although
the intracellular functions of RGD require further inves-
tigation, studies concerning proprotein convertase 1
showed that this sequence is essential for correct folding
in the endoplasmatic reticulum and transport to secre-
tory glands [45].
Micelles with cyclic RGD peptides transfected into
HeLa cells tend to congregate in the perinuclear region
[ 4 6 ] .T h e r e f o r e ,t h eR G Ds e q u e n c ei nN S 5 Ag e n o t y p e s
1 and 3 could have a role in (1) folding and intracellular
transport and/or (2) nuclear and perinuclear localiza-
tion. The NS5A protein has a functional nuclear loca-
tion signal (NLS) at its carboxy terminal [47]. The
complete protein form is predominantly located in the
cytoplasm and/or in the perinuclear region [47,48].
However, forms in which the NS5A amino terminal
region (residues 1-31) has been deleted predominate in
the nucleus [49]. These deleted forms occur naturally
during infection, resulting in cell caspase activity [50,51].
The function of these nuclear forms requires further
study but they have been shown to be transcriptional
regulators [52-54]. Furthermore, these forms can trans-
port other proteins complexed with NS5A. The c-Raf
protein interacts with the NS5A carboxy terminal and is
detected in the cell nucleus with these deleted forms of
the NS5A protein [54].
Regarding these studies, we suggest that the factors
participating in NS5A nuclear localization are (1) dele-
tion of the amino terminal region, which inhibits the
NLS region; (2) presence of the NLS without mutations;
(3) possible interactions between RGD and proteins
related to transport through the nuclear envelope (4)
possible glycosylation of NS5A similar to other nuclear
functional proteins.
It is important to highlight that if other proteins are
transported to the nucleus with c-Raf, nuclear NS5A
could be important to the regulation and modulation of
cell processes.
Conclusions
This research presents new insights regarding HCV
NS5A genotypes 1 and 3. In addition, it demonstrates
the importance of applying bioinformatic tools to the
Yamasaki et al. Virology Journal 2012, 9:14
http://www.virologyj.com/content/9/1/14
Page 7 of 10study of proteins that are difficult to investigate by other
experimental procedures. There was no relationship
between the response to therapy and primary structure,
but for genotype 3 secondary structure variances were
different between the three outcome groups. In addition,
there is evidence that the primary/secondary structure
differs among genotypes and that this could be impor-
tant during the infection process. Functional prediction
also indicated that NS5A may have functional difference
between genotypes. Altogether, structural and functional
properties show that the two genotypes behaviour dur-
ing infection have differences. The acquired data can be
compared with future experimental data regarding the
NS5A protein and may help in developing new antiviral
strategies, considering the genotypic differences present
in Hepatitis C virus.
Materials and methods
Sequence bank
T h es e q u e n c eb a n ki n c l u d e d3 4 5N S 5 Ac o m p l e t e
sequences that were obtained from previous studies by
our group [24,25] and nine reference sequences from
Genbank. These sequences were extracted from 23 Bra-
zilian patients infected with HCV genotypes 1a, 1b or 3.
The accession numbers in Genbank are
EU309511aEU309673 for genotype 1; EU826174 to
EU826233 and from EU826249 to EU826352 for geno-
type 3. These samples comprised patients who had a
sustained virological response (SVR), non response (NR)
or end of treatment response (ETR) after conventional
therapy based on Interferon (genotype 3) or Peginter-
feron (genotype 1) plus Ribavirin. Details of the study
population are presented in Table 4. Redundant amino
acid sequences were excluded, using the software
LOCQSPEC 1.0 [55], resulting in 252 different
sequences of complete NS5A.
Amino acids and secondary structure analysis
The percentage of each amino acid type was calculated
and secondary structures investigated in all complete
NS5A sequences from the sequence bank. These calcu-
lations were performed using the PROF program [56],
using the Predict Protein Server http://www.predictpro-
tein.org[57].
Transmembrane region prediction
Prediction of transmembrane regions was developed by
the MEMSAT3 program [58]http://bioinf.cs.ucl.ac.uk/
psipred/. All NS5A sequences from the sequence bank
were analyzed using this program.
Prediction of sites
All sequences were analyzed using the PROSITE pro-
gram [59], from the Predict Protein Server [57]. Prosite
is a pattern data bank, based on scientific publications
or research describing the function of determined pro-
tein groups [59].
Prediction of functional features
Sequences were submitted to ProtFun 2.2 Server. The
method is based on sequence derived protein features
such as predicted post translational modifications, pro-
tein sorting signals and physical/chemical properties
calculated from amino acid composition. This allows
prediction of functionality for proteins which no
homology can be found [60,61]. Acquired data were
organized in tables (not shown) to posterior statistical
analysis.
Statistical analysis
In order to establish if there were differences between
the prediction results between the response groups or
genotypes, test of homogeneity (chi-square test), t-test
and equal variance test was calculated using the soft-
ware MiniTab
® 15 (Minitab Inc., USA). Values under 5
(five) were excluded from statistical calculation, since
these results could be deviation from the sample. Statis-
tical power calculation was performed using online soft-
ware Russ Lenth’s power and sample size page [62].
Table 4 Characteristics of the study population and
number of NS5A different sequences
Patient # Genotype Therapy outcome No. of sequences
RF03 1A ETR 12
RF37 1A ETR 11
RF42 1B ETR 14
RF45 1A ETR 13
RF16 1A NR 13
RF22 1B NR 5
RF39 1B NR 3
RF44 1B NR 11
RF05 1B R 12
RF35 1A R 10
RF40 1A R 5
RF20 3 ETR 14
RF31 3 ETR 10
RF109 3 ETR 13
RF119 3 ETR 12
RF07 3 NR 12
RF60 3 NR 8
RF75 3 NR 12
RF145 3 NR 10
RF80 3 R 14
RF15 3 R 10
RF18 3 R 15
RF59 3 R 13
TOTAL - - 252
Yamasaki et al. Virology Journal 2012, 9:14
http://www.virologyj.com/content/9/1/14
Page 8 of 10Acknowledgements
This work was supported by grants from FAPESP, CNPq and CAPES.
Author details
1Department of Biology, Sao Paulo State University–UNESP, Sao Jose do Rio
Preto, SP, Brazil.
2Department of Clinical Medicine, Sao Paulo University–USP,
Medicine College, Sao Paulo, SP, Brazil.
3Viral Immunology Laboratory,
Butantan Institute, Sao Paulo, SP, Brazil.
4Rua Cristovao Colombo, 2265
Laboratorio de Estudos Genomicos, Jardim Nazareth, CEP: 15054-000, Sao
Jose do Rio Preto, SP, Brazil.
Authors’ contributions
LHTY carried out all experiments, acquisition of data, analysis and
interpretation of data, and drafting the manuscript; HAA helped with the
acquisition of data and interpretation of results; ACGJ, CB and IMVGCM
participated in the study and the writing of the manuscript, PR conceived
the study, participated in its analysis and coordination, and supplied
suggestions for this manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 5 July 2011 Accepted: 12 January 2012
Published: 12 January 2012
References
1. Gale M Jr, Foy EM: Evasion of intracellular host defence by hepatitis C
virus. Nature 2005, 436:939-945.
2. Appel N, Zayas M, Miller S, Krijnse-Locker J, Schaller T, Friebe P, Kallis S,
Engel U, Bartenschlager R: Essential role of domain III of nonstructural
protein 5A for hepatitis C virus infectious particle assembly. PLoS Pathog
2008, 4:e1000035.
3. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G:
Detection of antibody to hepatitis C virus in prospectively followed
transfusion recipients with acute and chronic non-A, non-B hepatitis. N
Engl J Med 1989, 321:1494-1500.
4. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S,
Watanabe Y, Koi S, Onji M, Ohta Y, et al: Hepatitis C virus infection is
associated with the development of hepatocellular carcinoma. Proc Natl
Acad Sci USA 1990, 87:6547-6549.
5. Simmonds P: Genetic diversity and evolution of hepatitis C virus-15
years on. J Gen Virol 2004, 85:3173-3188.
6. Kuiken C, Simmonds P: Nomenclature and numbering of the hepatitis C
virus. Methods Mol Biol 2009, 510:33-53.
7. Moradpour D, Cerny A, Heim MH, Blum HE: Hepatitis C: an update. Swiss
Med Wkly 2001, 131:291-298.
8. Pybus OG, Charleston MA, Gupta S, Rambaut A, Holmes EC, Harvey PH: The
epidemic behavior of the hepatitis C virus. Science 2001, 292:2323-2325.
9. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ,
Perelson AS: Hepatitis C viral dynamics in vivo and the antiviral efficacy
of interferon-alpha therapy. Science 1998, 282:103-107.
10. Moradpour D, Blum HE: A primer on the molecular virology of hepatitis
C. Liver Int 2004, 24:519-525.
11. Lyra AC, Fan X, Di Bisceglie AM: Molecular biology and clinical implication
of hepatitis C virus. Braz J Med Biol Res 2004, 37:691-695.
12. Kamar N, Bendall RP, Peron JM, Cintas P, Prudhomme L, Mansuy JM,
Rostaing L, Keane F, Ijaz S, Izopet J, Dalton HR: Hepatitis E virus and
neurologic disorders. Emerg Infect Dis 2011, 17:173-179.
13. Reed KE, Xu J, Rice CM: Phosphorylation of the hepatitis C virus NS5A
protein in vitro and in vivo: properties of the NS5A-associated kinase. J
Virol 1997, 71:7187-7197.
14. Macdonald A, Harris M: Hepatitis C virus NS5A: tales of a promiscuous
protein. J Gen Virol 2004, 85:2485-2502.
15. Liang Y, Ye H, Kang CB, Yoon HS: Domain 2 of nonstructural protein 5A
(NS5A) of hepatitis C virus is natively unfolded. Biochemistry 2007,
46:11550-11558.
16. Love RA, Brodsky O, Hickey MJ, Wells PA, Cronin CN: Crystal structure of a
novel dimeric form of NS5A domain I protein from hepatitis C virus. J
Virol 2009, 83:4395-4403.
17. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM: The NS5A
protein of hepatitis C virus is a zinc metalloprotein. J Biol Chem 2004,
279:48576-48587.
18. Moradpour D, Brass V, Penin F: Function follows form: the structure of the
N-terminal domain of HCV NS5A. Hepatology 2005, 42:732-735.
19. Brass V, Bieck E, Montserret R, Wolk B, Hellings JA, Blum HE, Penin F,
Moradpour D: An amino-terminal amphipathic alpha-helix mediates
membrane association of the hepatitis C virus nonstructural protein 5A.
J Biol Chem 2002, 277:8130-8139.
20. Liu S, Ansari IH, Das SC, Pattnaik AK: Insertion and deletion analyses
identify regions of non-structural protein 5A of Hepatitis C virus that are
dispensable for viral genome replication. J Gen Virol 2006, 87:323-327.
21. Verdegem D, Badillo A, Wieruszeski JM, Landrieu I, Leroy A,
Bartenschlager R, Penin F, Lippens G, Hanoulle X: Domain 3 of NS5A
protein from the hepatitis C virus has intrinsic {alpha}-helical propensity
and is a substrate of Cyclophilin A. J Biol Chem 2011.
22. Wohnsland A, Hofmann WP, Sarrazin C: Viral determinants of resistance to
treatment in patients with hepatitis C. Clin Microbiol Rev 2007, 20:23-38.
23. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP,
Perelson AS, Layden TJ: Differences in viral dynamics between genotypes
1 and 2 of hepatitis C virus. J Infect Dis 2000, 182:28-35.
24. Jardim AC, Yamasaki LH, de Queiroz AT, Bittar C, Pinho JR, Carareto CM,
Rahal P, Mello IM: Quasispecies of hepatitis C virus genotype 1 and
treatment outcome with peginterferon and ribavirin. Infect Genet Evol
2009, 9:89-698.
25. Bittar C, Jardim AC, Yamasaki LH, de Queiroz AT, Carareto CM, Pinho JR, de
Carvalho-Mello IM, Rahal P: Genetic diversity of NS5A protein from
hepatitis C virus genotype 3a and its relationship to therapy response.
BMC Infect Dis 2010, 10:36.
26. Tsai YH, Kuang WF, Lu TY, Kao JH, Lai MY, Liu CJ, Chen PJ, Hwang LH: The
non-structural 5A protein of hepatitis C virus exhibits genotypic
differences in interferon antagonism. J Hepatol 2008, 49:899-907.
27. Kang SM, Won SJ, Lee GH, Lim YS, Hwang SB: Modulation of interferon
signaling by hepatitis C virus non-structural 5A protein: implication of
genotypic difference in interferon treatment. FEBS Lett 2010,
584:4069-4076.
28. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J: Recombinant HCV
variants with NS5A from genotypes 1-7 have different sensitivities to an
NS5A inhibitor but not interferon-alpha. Gastroenterology 2011,
140:1032-1042.
29. Schreiber G, Keating AE: Protein binding specificity versus promiscuity.
Curr Opin Struct Biol 2011, 21:50-61.
30. Taylor ME, Drickamer K: Structural requirements for high affinity binding
of complex ligands by the macrophage mannose receptor. J Biol Chem
1993, 268:399-404.
31. Petrescu AJ, Milac AL, Petrescu SM, Dwek RA, Wormald MR: Statistical
analysis of the protein environment of N-glycosylation sites: implications
for occupancy, structure, and folding. Glycobiology 2004, 14:103-114.
32. Graff J, Zhou YH, Torian U, Nguyen H, St Claire M, Yu C, Purcell RH,
Emerson SU: Mutations within potential glycosylation sites in the capsid
protein of hepatitis E virus prevent the formation of infectious virus
particles. J Virol 2008, 82:1185-1194.
33. Helenius A: How N-linked oligosaccharides affect glycoprotein folding in
the endoplasmic reticulum. Mol Biol Cell 1994, 5:253-265.
34. Hart GW, Haltiwanger RS, Holt GD, Kelly WG: Glycosylation in the nucleus
and cytoplasm. Annu Rev Biochem 1989, 58:841-874.
35. Pedemonte CH, Sachs G, Kaplan JH: An intrinsic membrane glycoprotein
with cytosolically oriented n-linked sugars. Proc Natl Acad Sci USA 1990,
87:9789-9793.
36. Kreppel LK, Blomberg MA, Hart GW: Dynamic glycosylation of nuclear and
cytosolic proteins. Cloning and characterization of a unique O-GlcNAc
transferase with multiple tetratricopeptide repeats. J Biol Chem 1997,
272:9308-9315.
37. Hart GW: Dynamic O-linked glycosylation of nuclear and cytoskeletal
proteins. Annu Rev Biochem 1997, 66:315-335.
38. Masaki T, Suzuki R, Murakami K, Aizaki H, Ishii K, Murayama A, Date T,
Matsuura Y, Miyamura T, Wakita T, Suzuki T: Interaction of hepatitis C virus
nonstructural protein 5A with core protein is critical for the production
of infectious virus particles. J Virol 2008, 82:7964-7976.
Yamasaki et al. Virology Journal 2012, 9:14
http://www.virologyj.com/content/9/1/14
Page 9 of 1039. Huang Y, Staschke K, De Francesco R, Tan SL: Phosphorylation of hepatitis
C virus NS5A nonstructural protein: a new paradigm for
phosphorylation-dependent viral RNA replication? Virology 2007, 364:1-9.
40. Tellinghuisen TL, Foss KL, Treadaway JC, Rice CM: Identification of residues
required for RNA replication in domains II and III of the hepatitis C virus
NS5A protein. J Virol 2008, 82:1073-1083.
41. Neddermann P: NS5A phosphorylation and hyperphosphorylation.
Methods Mol Biol 2009, 510:95-110.
42. Gordon JI, Duronio RJ, Rudnick DA, Adams SP, Gokel GW: Protein N-
myristoylation. J Biol Chem 1991, 266:8647-8650.
43. Farazi TA, Waksman G, Gordon JI: The biology and enzymology of protein
N-myristoylation. J Biol Chem 2001, 276:39501-39504.
44. Ruoslahti E, Pierschbacher MD: Arg-Gly-Asp: a versatile cell recognition
signal. Cell 1986, 44:517-518.
45. Rovere C, Luis J, Lissitzky JC, Basak A, Marvaldi J, Chretien M, Seidah NG:
The RGD motif and the C-terminal segment of proprotein convertase 1
are critical for its cellular trafficking but not for its intracellular binding
to integrin alpha5beta1. J Biol Chem 1999, 274:12461-12467.
46. Oba M, Aoyagi K, Miyata K, Matsumoto Y, Itaka K, Nishiyama N, Yamasaki Y,
Koyama H, Kataoka K: Polyplex micelles with cyclic RGD peptide ligands
and disulfide cross-links directing to the enhanced transfection via
controlled intracellular trafficking. Mol Pharm 2008, 5:1080-1092.
47. Ide Y, Zhang L, Chen M, Inchauspe G, Bahl C, Sasaguri Y, Padmanabhan R:
Characterization of the nuclear localization signal and subcellular
distribution of hepatitis C virus nonstructural protein NS5A. Gene 1996,
182:203-211.
48. Kim JE, Song WK, Chung KM, Back SH, Jang SK: Subcellular localization of
hepatitis C viral proteins in mammalian cells. Arch Virol 1999, 144:329-343.
49. Song J, Nagano-Fujii M, Wang F, Florese R, Fujita T, Ishido S, Hotta H:
Nuclear localization and intramolecular cleavage of N-terminally deleted
NS5A protein of hepatitis C virus. Virus Res 2000, 69:109-117.
50. Hidajat R, Nagano-Fujii M, Deng L, Hotta H: Cleavage of the hepatitis C
virus NS5A protein by caspase-3 in the interferon sensitivity-determining
region in a sequence-dependent manner. Kobe J Med Sci 2004,
50:153-166.
51. Kalamvoki M, Georgopoulou U, Mavromara P: The NS5A protein of the
hepatitis C virus genotype 1a is cleaved by caspases to produce C-
terminal-truncated forms of the protein that reside mainly in the
cytosol. J Biol Chem 2006, 281:13449-13462.
52. Tanimoto A, Ide Y, Arima N, Sasaguri Y, Padmanabhan R: The amino
terminal deletion mutants of hepatitis C virus nonstructural protein
NS5A function as transcriptional activators in yeast. Biochem Biophys Res
Commun 1997, 236:360-364.
53. Fukuma T, Enomoto N, Marumo F, Sato C: Mutations in the interferon-
sensitivity determining region of hepatitis C virus and transcriptional
activity of the nonstructural region 5A protein. Hepatology 1998,
28:1147-1153.
54. Sauter D, Himmelsbach K, Kriegs M, Carvajal Yepes M, Hildt E: Localization
determines function: N-terminally truncated NS5A fragments accumulate
in the nucleus and impair HCV replication. J Hepatol 2009, 50:861-871.
55. Marucci EA, Zafalon GF, Jardim AC, Yamasaki LH, Bittar C, Rahal P,
Machado JM: Routine libraries for pattern recognition in quasispecies.
Genet Mol Res 2008, 7:970-981.
56. Rost B, Sander C: Improved prediction of protein secondary structure by
use of sequence profiles and neural networks. Proc Natl Acad Sci USA
1993, 90:7558-7562.
57. Rost B, Yachdav G, Liu J: The predictprotein server. Nucleic Acids Res 2004,
32:W321-W326.
58. Jones DT: Improving the accuracy of transmembrane protein topology
prediction using evolutionary information. Bioinformatics 2007, 23:538-544.
59. Bairoch A, Bucher P, Hofmann K: The PROSITE database, its status in 1997.
Nucleic Acids Res 1997, 25:217-221.
60. Jensen LJ, Gupta R, Blom N, Devos D, Tamames J, Kesmir C, Nielsen H,
Staerfeldt HH, Rapacki K, Workman C, et al: Prediction of human protein
function from post-translational modifications and localization features. J
Mol Biol 2002, 319:1257-1265.
61. Jensen LJ, Ussery DW, Brunak S: Functionality of system components:
conservation of protein function in protein feature space. Genome Res
2003, 13:2444-2449.
62. Lenth RV: Java Applets for Power and Sample Size [Computer software].
Java Applets for Power and Sample Size 2006-9[http://www.stat.uiowa.edu/
~rlenth/Power/].
doi:10.1186/1743-422X-9-14
Cite this article as: Yamasaki et al.: New insights regarding HCV-NS5A
structure/function and indication of genotypic differences. Virology
Journal 2012 9:14.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Yamasaki et al. Virology Journal 2012, 9:14
http://www.virologyj.com/content/9/1/14
Page 10 of 10